Spots Global Cancer Trial Database for Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Official Title: An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer
Study ID: NCT05712889
Conditions
Interventions
Study Description
Brief Summary: Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
Detailed Description: All comers solid tumor subjects with histologically confirmed advanced or metastatic disease who have relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Honor Health, Scottsdale, Arizona, United States
NEXT Austin, Austin, Texas, United States
NEXT Oncology San Antonio, San Antonio, Texas, United States
Macquarie University, Macquarie Park, New South Wales, Australia
ICON Brisbane, Brisbane, Queensland, Australia
ICON Adelaide, Adelaide, Southern Australia, Australia
Contact Details
Name: Vincerx Study Director
Affiliation: Vincerx Pharma, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
